Osaic Holdings’s Calidi Biotherapeutics CLDI Stock Holding History

Osaic Holdings’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450	Buy	166 +34	+26%	+$110	﹤0.01%	7673
2026 Q1	$503	Hold	132	–	–	﹤0.01%	7436
2025 Q4	$2.46K	Buy	132 +107	+428%	+$2.52K	﹤0.01%	7019
2025 Q3	$377	Sell	25 -114	-82%	-$7.75K	﹤0.01%	7595
2025 Q2	$6.15K	Buy	139 +39	+39%	+$3.03K	﹤0.01%	6423
2025 Q1	$10.9K	Buy	100 +96	+2,400%	+$17.5K	﹤0.01%	5737
2024 Q4	$865	Buy	4 +3	+300%	+$900	﹤0.01%	6889
2024 Q3	$288	Hold	1	–	–	﹤0.01%	7112
2024 Q2	$505	Hold	1	–	–	﹤0.01%	6978
2024 Q1	$1.44K	Buy	+1	New	+$1.63K	﹤0.01%	6588

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Osaic Holdings's CLDI Position: Q2 2026 in Review

Osaic Holdings increased its Calidi Biotherapeutics (CLDI) stake by 26% in Q2 2026, buying an estimated $110 and bringing the position to 166 shares worth $450. The position accounts for ﹤0.01% of the portfolio, ranked #7673.

Osaic Holdings first reported a position in CLDI in Q1 2024 and has held it in 10 quarters since. The position peaked at $10.9K in Q1 2025. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Osaic Holdings held 166 shares of Calidi Biotherapeutics worth $450 as of Q2 2026.
Osaic Holdings bought 34 Calidi Biotherapeutics shares in Q2 2026, an estimated $110.
Calidi Biotherapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7673 holding.
Osaic Holdings first reported a position in Calidi Biotherapeutics in Q1 2024 and has held it in 10 quarters since.
Osaic Holdings's Calidi Biotherapeutics position peaked at $10.9K in Q1 2025.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.